{"id":117955,"date":"2025-08-29T08:09:09","date_gmt":"2025-08-29T08:09:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/117955\/"},"modified":"2025-08-29T08:09:09","modified_gmt":"2025-08-29T08:09:09","slug":"branchio-oto-renal-syndrome-in-a-young-han-chinese-female-a-case-report-and-review-of-the-literature-journal-of-medical-case-reports","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/117955\/","title":{"rendered":"Branchio-oto-renal syndrome in a young Han Chinese female: a case report and review of the literature | Journal of Medical Case Reports"},"content":{"rendered":"<p>BORS is a rare autosomal dominant genetic disorder with significant heterogeneity in clinical practice, and the penetrance rate is highly variable even within the same family. Research has shown that BORS exhibits hearing loss (noticed in 98.5% of cases), gill abnormalities (49\u201373%), preauricular depression (53\u201383%), and renal abnormalities (38\u201370%) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 4\" title=\"Stinckens C, Standaert L, Casselman JW, Huygen PL, Kumar S, Van de Wallen J, et\u00a0al. The presence of a widened vestibular aqueduct and progressive sensorineural hearing loss in the branchio-oto-renal syndrome. A family study. Int J Pediatr Otorhinolaryngol. 2001;59(3):163\u201372.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR4\" id=\"ref-link-section-d135655707e614\" rel=\"nofollow noopener\" target=\"_blank\">4<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 5\" title=\"Masuda M, Kanno A, Nara K, Mutai H, Morisada N, Iijima K, et\u00a0al. Phenotype-genotype correlation in patients with typical and atypical branchio-oto-renal syndrome. Sci Rep. 2022;12(1):969.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR5\" id=\"ref-link-section-d135655707e617\" rel=\"nofollow noopener\" target=\"_blank\">5<\/a>]. In addition to the typical clinical manifestations of ears, gills, and kidneys mentioned above, many studies have also reported other accompanying symptoms of BORS, such as developmental delay, intellectual disability, hypospadias, and bone defects. [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Morisada N, Nozu K, Iijima K. Branchio-oto-renal syndrome: comprehensive review based on nationwide surveillance in Japan. Pediatr Int. 2014;56(3):309\u201314.\" href=\"#ref-CR6\" id=\"ref-link-section-d135655707e620\">6<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Salinas-Torres VM, Rivera H. Branchiootorenal syndrome with skeletal defects: a novel association in a Mexican child. Clin Dysmorphol. 2015;24(1):21\u20133.\" href=\"#ref-CR7\" id=\"ref-link-section-d135655707e620_1\">7<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 8\" title=\"Dutta M, Chatterjee I. Hypospadias as a new entity to define the branchio-oto-renal spectrum disorders. Ear Nose Throat J. 2019;98(1):20\u20132.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR8\" id=\"ref-link-section-d135655707e623\" rel=\"nofollow noopener\" target=\"_blank\">8<\/a>]. Hearing loss is the most common symptom of BORS, with 64\u2013100% of patients experiencing some degree of hearing loss [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 3\" title=\"Chang EH, Menezes M, Meyer NC, Cucci RA, Vervoort VS, Schwartz CE, et\u00a0al. Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat. 2004;23(6):582\u20139.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR3\" id=\"ref-link-section-d135655707e626\" rel=\"nofollow noopener\" target=\"_blank\">3<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"Morisada N, Nozu K, Iijima K. Branchio-oto-renal syndrome: comprehensive review based on nationwide surveillance in Japan. Pediatr Int. 2014;56(3):309\u201314.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR6\" id=\"ref-link-section-d135655707e630\" rel=\"nofollow noopener\" target=\"_blank\">6<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Unzaki A, Morisada N, Nozu K, Ye MJ, Ito S, Matsunaga T, et\u00a0al. Clinically diverse phenotypes and genotypes of patients with branchio-oto-renal syndrome. J Hum Genet. 2018;63(5):647\u201356.\" href=\"#ref-CR9\" id=\"ref-link-section-d135655707e633\">9<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Krug P, Morini\u00e8re V, Marlin S, Koubi V, Gabriel HD, Colin E, et\u00a0al. Mutation screening of the EYA1, SIX1, and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations. Hum Mutat. 2011;32(2):183\u201390.\" href=\"#ref-CR10\" id=\"ref-link-section-d135655707e633_1\">10<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 11\" title=\"Smith RJ, Schwartz C. Branchio-oto-renal syndrome. J Commun Disord. 1998;31 (5):411\u201320; (quiz 21).\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR11\" id=\"ref-link-section-d135655707e636\" rel=\"nofollow noopener\" target=\"_blank\">11<\/a>]. Mixed hearing loss is the most common type of hearing loss in patients with BORS (33.7\u201350%), followed by sensorineural (10.98\u201329.8%) and conductive (7.84\u201330%) hearing loss [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 6\" title=\"Morisada N, Nozu K, Iijima K. Branchio-oto-renal syndrome: comprehensive review based on nationwide surveillance in Japan. Pediatr Int. 2014;56(3):309\u201314.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR6\" id=\"ref-link-section-d135655707e639\" rel=\"nofollow noopener\" target=\"_blank\">6<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Smith RJ, Schwartz C. Branchio-oto-renal syndrome. J Commun Disord. 1998;31 (5):411\u201320; (quiz 21).\" href=\"#ref-CR11\" id=\"ref-link-section-d135655707e642\">11<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Lindau TA, Cardoso AC, Rossi NF, Giacheti CM. Anatomical changes and audiological profile in branchio-oto-renal syndrome: a literature review. Int Arch Otorhinolaryngol. 2014;18(1):68\u201376.\" href=\"#ref-CR12\" id=\"ref-link-section-d135655707e642_1\">12<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 13\" title=\"Chen A, Francis M, Ni L, Cremers CW, Kimberling WJ, Sato Y, et\u00a0al. Phenotypic manifestations of branchio-oto-renal syndrome. Am J Med Genet. 1995;58(4):365\u201370.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR13\" id=\"ref-link-section-d135655707e645\" rel=\"nofollow noopener\" target=\"_blank\">13<\/a>]. Imaging studies have shown that structural abnormalities in the inner\/middle ear, such as underdeveloped cochlea and enlarged vestibular aqueduct, are closely related to the progression of hearing impairment. Imaging studies can detect abnormalities in the inner ear (18\u201392%) and\/or middle ear (15\u2013100%) of BORS [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 9\" title=\"Unzaki A, Morisada N, Nozu K, Ye MJ, Ito S, Matsunaga T, et\u00a0al. Clinically diverse phenotypes and genotypes of patients with branchio-oto-renal syndrome. J Hum Genet. 2018;63(5):647\u201356.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR9\" id=\"ref-link-section-d135655707e649\" rel=\"nofollow noopener\" target=\"_blank\">9<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 14\" title=\"Ideura M, Nishio SY, Moteki H, Takumi Y, Miyagawa M, Sato T, et\u00a0al. Comprehensive analysis of syndromic hearing loss patients in Japan. Sci Rep. 2019;9(1):11976.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR14\" id=\"ref-link-section-d135655707e652\" rel=\"nofollow noopener\" target=\"_blank\">14<\/a>]. Cochlear hypoplasia is the most common inner ear abnormality (33\u2013100%), followed by vestibular aqueduct enlargement (24\u201350%) and inner ear canal abnormalities (17\u201386%) [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 13\" title=\"Chen A, Francis M, Ni L, Cremers CW, Kimberling WJ, Sato Y, et\u00a0al. Phenotypic manifestations of branchio-oto-renal syndrome. Am J Med Genet. 1995;58(4):365\u201370.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR13\" id=\"ref-link-section-d135655707e655\" rel=\"nofollow noopener\" target=\"_blank\">13<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 15\" title=\"Propst EJ, Blaser S, Gordon KA, Harrison RV, Papsin BC. Temporal bone findings on computed tomography imaging in branchio-oto-renal syndrome. Laryngoscope. 2005;115(10):1855\u201362.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR15\" id=\"ref-link-section-d135655707e658\" rel=\"nofollow noopener\" target=\"_blank\">15<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 16\" title=\"Kemperman MH, Koch SM, Joosten FB, Kumar S, Huygen PL, Cremers CW. Inner ear anomalies are frequent but nonobligatory features of the branchio-oto-renal syndrome. Arch Otolaryngol Head Neck Surg. 2002;128(9):1033\u20138.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR16\" id=\"ref-link-section-d135655707e661\" rel=\"nofollow noopener\" target=\"_blank\">16<\/a>]. Kemperman analyzed long-term series audiometry data of patients with BORS, and the results showed that patients with BORS with large endolymphatic vessels and\/or cysts on MRI seemed more likely to develop more severe hearing impairment. Furthermore, in clinical practice, about 70% of patients with hearing loss do not progress, and 30% of patients with progressive hearing loss often suffer from vestibular aqueduct enlargement [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 17\" title=\"Kemperman MH, Koch SM, Kumar S, Huygen PL, Joosten FB, Cremers CW. Evidence of progression and fluctuation of hearing impairment in branchio-oto-renal syndrome. Int J Audiol. 2004;43(9):523\u201332.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR17\" id=\"ref-link-section-d135655707e664\" rel=\"nofollow noopener\" target=\"_blank\">17<\/a>].<\/p>\n<p>The patient presented with bilateral branchial fistula, preauricular fistula, auricular malformation, large vestibular aqueduct, and left renal dysplasia, which meet the diagnostic criteria of BORS. For this patient, we removed both fistulas separately, ensuring the integrity of the anatomical structure while reducing the risk of fistula recurrence. There is no cure for BORS in patients with sensorineural hearing loss, and wearing hearing aids can be used as an adjuvant treatment. For patients with BORS who cannot obtain good hearing assistance from hearing aids, cochlear implantation is expected to serve as an alternative approach, enabling patients with advanced hearing impairment to achieve a good hearing prognosis. In this case report, the patient suffered from bilateral sensorineural hearing loss, but the patient consciously did not have significant hearing loss, which may be related to the fact that the patient has adapted to hearing loss. Patients may need to use hearing aids or cochlear implants to further improve hearing. In addition, the patient also has an enlarged vestibular aqueduct, which predisposes them to progressive hearing loss. Therefore, hearing should be checked at least every 6\u00a0months, and ototoxic medications should be avoided to prevent further hearing deterioration. BORS exhibits high heterogeneity in renal malformations, with clinical manifestations ranging from mild structural abnormalities to end-stage renal disease. The latest research shows that about 10\u201320% of patients with BORS have renal abnormalities, including renal dysplasia (such as volume reduction or structural disorder), unilateral\/bilateral kidney absence, polycystic kidney disease, ureteral dilation, or hydronephrosis [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 18\" title=\"Weber S, Moriniere V, Kn\u00fcppel T, Charbit M, Dusek J, Ghiggeri GM, et\u00a0al. Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. J Am Soc Nephrol. 2006;17(10):2864\u201370.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR18\" id=\"ref-link-section-d135655707e670\" rel=\"nofollow noopener\" target=\"_blank\">18<\/a>]. Among them, 6% of cases present with severe renal malformations (such as bilateral renal hypoplasia), which may progress to chronic renal failure within 20\u00a0years after birth and require dialysis or kidney transplantation [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 19\" title=\"Izzedine H, Tankere F, Launay-Vacher V, Deray G. Ear and kidney syndromes: molecular versus clinical approach. Kidney Int. 2004;65(2):369\u201385.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR19\" id=\"ref-link-section-d135655707e673\" rel=\"nofollow noopener\" target=\"_blank\">19<\/a>]. Severe kidney deformities can also lead to Potter\u2019s facial features, including wide eye distance, low ear position, mandibular retraction, and flat nose [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 20\" title=\"Carmi R, Binshtock M, Abeliovich D, Bar-Ziv J. The branchio-oto-renal (BOR) syndrome: report of bilateral renal agenesis in three sibs. Am J Med Genet. 1983;14(4):625\u20137.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR20\" id=\"ref-link-section-d135655707e676\" rel=\"nofollow noopener\" target=\"_blank\">20<\/a>]. In this case, the patient had unilateral renal dysplasia and required regular monitoring and management of renal abnormalities, including at least biannual ultrasound examinations and estimated glomerular filtration rate (eGFR) monitoring, to prevent the progression of end-stage renal disease. In recent years, significant progress has been made in the genetic research of BORS. Research has found that mutations in the EYA1, SIX1, and SIX5 genes are closely related to BORS, with the EYA1 gene being the most common pathogenic gene [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 3\" title=\"Chang EH, Menezes M, Meyer NC, Cucci RA, Vervoort VS, Schwartz CE, et\u00a0al. Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat. 2004;23(6):582\u20139.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR3\" id=\"ref-link-section-d135655707e692\" rel=\"nofollow noopener\" target=\"_blank\">3<\/a>]. In the European and American populations, about 40% of patients carry this gene mutation [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 3\" title=\"Chang EH, Menezes M, Meyer NC, Cucci RA, Vervoort VS, Schwartz CE, et\u00a0al. Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat. 2004;23(6):582\u20139.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR3\" id=\"ref-link-section-d135655707e695\" rel=\"nofollow noopener\" target=\"_blank\">3<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 21\" title=\"Brophy PD, Alasti F, Darbro BW, Clarke J, Nishimura C, Cobb B, et\u00a0al. Genome-wide copy number variation analysis of a Branchio-oto-renal syndrome cohort identifies a recombination hotspot and implicates new candidate genes. Hum Genet. 2013;132(12):1339\u201350.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR21\" id=\"ref-link-section-d135655707e698\" rel=\"nofollow noopener\" target=\"_blank\">21<\/a>]. The protein encoded by the EYA1 gene plays an important role in embryonic development, especially in the development of gill arches, ears, and kidneys [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 9\" title=\"Unzaki A, Morisada N, Nozu K, Ye MJ, Ito S, Matsunaga T, et\u00a0al. Clinically diverse phenotypes and genotypes of patients with branchio-oto-renal syndrome. J Hum Genet. 2018;63(5):647\u201356.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR9\" id=\"ref-link-section-d135655707e705\" rel=\"nofollow noopener\" target=\"_blank\">9<\/a>]. Research has shown that the EYA1 gene regulates organogenesis. Mutations in human EYA1 can lead to BORS, while targeted inactivation of mouse EYA1 can impair early development of multiple organs.. In addition, EYA1 is also involved in controlling key early induction events involved in thymus, parathyroid, and thyroid morphogenesis [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 22\" title=\"Xu PX, Zheng W, Laclef C, Maire P, Maas RL, Peters H, et\u00a0al. Eya1 is required for the morphogenesis of mammalian thymus, parathyroid and thyroid. Development. 2002;129(13):3033\u201344.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR22\" id=\"ref-link-section-d135655707e720\" rel=\"nofollow noopener\" target=\"_blank\">22<\/a>]. In addition to BORS, the EYA1 gene is also closely related to the occurrence and development of stem cell carcinoma, melanoma, breast cancer, and other tumors [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Zhou JJ, Huang Y, Zhang X, Cheng Y, Tang L, Ma X. Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma. Oncotarget. 2017;8(62):105081\u201392.\" href=\"#ref-CR23\" id=\"ref-link-section-d135655707e727\">23<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" title=\"Kong D, Ma W, Zhang D, Cui Q, Wang K, Tang J, et\u00a0al. EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma. Am J Transl Res. 2019;11(4):2328\u201338.\" href=\"#ref-CR24\" id=\"ref-link-section-d135655707e727_1\">24<\/a>,<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 25\" title=\"Guan H, Dai Z, Ma Y, Wang Z, Liu X, Wang X. Microrna-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer. Int J Mol Med. 2016;37(6):1643\u201351.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR25\" id=\"ref-link-section-d135655707e730\" rel=\"nofollow noopener\" target=\"_blank\">25<\/a>].<\/p>\n<p>About 4% of patients with BORS carry the SIX1 gene mutation [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 26\" title=\"Kochhar A, Orten DJ, Sorensen JL, Fischer SM, Cremers CW, Kimberling WJ, et\u00a0al. SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent missense mutation associated with BOR. Hum Mutat. 2008;29(4):565.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR26\" id=\"ref-link-section-d135655707e739\" rel=\"nofollow noopener\" target=\"_blank\">26<\/a>]. The SIX1 gene is regulated by the EYA1 gene, and the SIX1\u2013EYA1 protein complex affects organ development during embryonic development by regulating cell proliferation and differentiation [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 27\" title=\"Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK, et\u00a0al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature. 2003;426(6964):247\u201354.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR27\" id=\"ref-link-section-d135655707e748\" rel=\"nofollow noopener\" target=\"_blank\">27<\/a>]. Recent studies have found that the SIX1 protein is involved in the regulation of expression patterns during early sensory development, and mutations can affect embryonic craniofacial gene expression and auditory sac development [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 28\" title=\"Shah AM, Krohn P, Baxi AB, Tavares ALP, Sullivan CH, Chillakuru YR, et\u00a0al. Six1 proteins with human branchio-oto-renal mutations differentially affect cranial gene expression and otic development. Dis Model Mech. 2020. &#010;                  https:\/\/doi.org\/10.1242\/dmm.043489&#010;                  &#010;                .\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR28\" id=\"ref-link-section-d135655707e752\" rel=\"nofollow noopener\" target=\"_blank\">28<\/a>, <a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 29\" title=\"Sato S, Furuta Y, Kawakami K. Regulation of continuous but complex expression pattern of Six1 during early sensory development. Dev Dyn. 2018;247(1):250\u201361.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR29\" id=\"ref-link-section-d135655707e755\" rel=\"nofollow noopener\" target=\"_blank\">29<\/a>]. In clinical practice, patients with gill kidney lineage diseases carrying SIX1 pathogenic mutations are more prone to severe sensorineural hearing loss [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 30\" title=\"Chen A, Song J, Acke FRE, Mei L, Cai X, Feng Y, et\u00a0al. Otological manifestations in branchiootorenal spectrum disorder: a systematic review and meta-analysis. Clin Genet. 2021;100(1):3\u201313.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR30\" id=\"ref-link-section-d135655707e761\" rel=\"nofollow noopener\" target=\"_blank\">30<\/a>]. About 5% of patients with BORS carry a pathogenic mutation in the SIX5 gene. Hoskins et\u00a0al. first discovered mutations in SIX5 in patients in 2007 and demonstrated that mutations affect the transcriptional activation of the SIX5 protein and SIX5\u2013EYA1 protein complex, indicating that SIX5 is a BORS-related gene [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 31\" title=\"Hoskins BE, Cramer CH, Silvius D, Zou D, Raymond RM, Orten DJ, et\u00a0al. Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome. Am J Hum Genet. 2007;80(4):800\u20134.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR31\" id=\"ref-link-section-d135655707e777\" rel=\"nofollow noopener\" target=\"_blank\">31<\/a>]. At present, it is believed that the pathogenic mechanism of SIX5 mutation is similar to that of the SIX1 mutation. However, no SIX5 mutation was found in the subsequent large-scale screening, and some cases were re attributed to EYA1 mutation, therefore its pathogenicity is questionable.<\/p>\n<p>In addition to the above three genes, nearly half of the patients still need to further explore the genetic basis of their pathogenic factors. Currently, new genes related to BORS are constantly being discovered. In 2014, Morisada reported a sporadic case of BORS in Japanese patients and found through array comparative genomic hybridization that a 6\u00a0Mb microdeletion on chromosome 16 of the SALL1 gene was associated with the BORS phenotype [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 32\" title=\"Morisada N, Sekine T, Ishimori S, Tsuda M, Adachi M, Nozu K, et\u00a0al. 16q12 microdeletion syndrome in two Japanese boys. Pediatr Int. 2014;56(5):e75\u20138.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR32\" id=\"ref-link-section-d135655707e799\" rel=\"nofollow noopener\" target=\"_blank\">32<\/a>]. SALL1 mutations are usually associated with Townes Brocks syndrome (manifested as anal atresia, ear deformities), partially overlapping with the clinical phenotype of BORS, but whether the pathogenic mechanism is directly related still needs to be verified [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 33\" title=\"Engels S, Kohlhase J, McGaughran J. A SALL1 mutation causes a branchio-oto-renal syndrome-like phenotype. J Med Genet. 2000;37(6):458\u201360.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR33\" id=\"ref-link-section-d135655707e805\" rel=\"nofollow noopener\" target=\"_blank\">33<\/a>]. In 2013, Brophy analyzed the whole genome copy number variations of 35 patients with BORS who did not have EYA1, SIX1, or SIX5 gene mutations and found that 17 of them had significant copy number variations (11 chromosomal microdeletions and 6 microduplications), thus identifying the chromosomal hotspots of BORS and discovering that the SHARPIN, FGF3, and HOXA gene clusters were potential pathogenic genes [<a data-track=\"click\" data-track-action=\"reference anchor\" data-track-label=\"link\" data-test=\"citation-ref\" aria-label=\"Reference 21\" title=\"Brophy PD, Alasti F, Darbro BW, Clarke J, Nishimura C, Cobb B, et\u00a0al. Genome-wide copy number variation analysis of a Branchio-oto-renal syndrome cohort identifies a recombination hotspot and implicates new candidate genes. Hum Genet. 2013;132(12):1339\u201350.\" href=\"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05515-5#ref-CR21\" id=\"ref-link-section-d135655707e824\" rel=\"nofollow noopener\" target=\"_blank\">21<\/a>].<\/p>\n<p>Genetic testing, such as multiplex ligation-dependent probe amplification (MLPA) and next-generation sequencing (NGS), has significant value in the diagnosis of BORS. MLPA can detect copy number variations in the EYA1 gene, while NGS can comprehensively screen for mutations in the EYA1, SIX1, and SIX5 genes. Despite the high cost of genetic testing, its potential application prospects in the diagnosis and genetic counseling of BORS are broad. Future research should further explore the application value of genetic testing in BORS diagnosis, especially in situations where resources are limited. Unfortunately, since the patient\u2019s family refused to proceed with further genetic testing, the type of gene mutation in this patient could not be verified. The lack of genetic testing not only confines the diagnostic basis of this case to clinical manifestations and imaging assessments but also significantly restricts the precise evaluation of genetic risks for the patient and their family. Confirmation of pathogenic variants in EYA1 or related genes would not only strengthen the diagnostic basis for BORS but also enable targeted genetic screening for other potential carriers in the family (such as parents and siblings). This would facilitate the early identification of recessive carriers and allow for risk communication, prenatal diagnosis, or genetic screening during their family planning, thereby significantly altering the family\u2019s reproductive decision-making and risk management strategies. Meanwhile, genetic testing can also guide the multidisciplinary team in developing more personalized follow-up and intervention plans. Since genetic testing was not performed in this case, it has, to some extent, limited the long-term management of the case and the provision of precise genetic counseling to the family members.<\/p>\n","protected":false},"excerpt":{"rendered":"BORS is a rare autosomal dominant genetic disorder with significant heterogeneity in clinical practice, and the penetrance rate&hellip;\n","protected":false},"author":2,"featured_media":117956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[76243,76241,257,5598,200,13349,5602,256,76242,5600,5599,76244,79,5601],"class_list":["post-117955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-branchial-fistula","tag-branchio-oto-renal-syndrome","tag-general","tag-general-practice-family-medicine","tag-genetics","tag-hearing-loss","tag-internal-medicine","tag-medicine-public-health","tag-preauricular-fistula","tag-primary-care-medicine","tag-public-health","tag-renal-dysplasia","tag-science","tag-surgical-oncology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/117955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=117955"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/117955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/117956"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=117955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=117955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=117955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}